Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot multicenter open study of peginterferon alfa-2a in HBeAg-negative chronic hepatitis B with residual viremia or virological rebound on nucleos(t)ide analogues
2008-004761-26Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Luigi Vanvitelli
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peginterferon alfa-2a in Chronic hepatitis B (CHB), sponsored by Azienda Ospedaliera Universitaria Luigi Vanvitelli. Primary endpoints: Primary efficacy endpoint and Primary tolerability endpoint. Started Dec 2008; status: terminated.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on 2008-004761-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004761-26.